Dexamethasone 1.5 Mg has 23 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amphotericin B, Amphotericin B Injection, Anticholinesterase Agents. Patients taking Dexamethasone 1.5 Mg should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Major
- 4
- Moderate
- 17
Major (4)
- Dexamethasone 1.5 Mg + Amphotericin B— Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.
- Dexamethasone 1.5 Mg + Amphotericin B Injection— Concomitant use with dexamethasone may lead to hypokalemia, cardiac enlargement, and congestive heart failure.
- Dexamethasone 1.5 Mg + Anticholinesterase Agents— Concomitant use with dexamethasone may produce severe weakness in patients with myasthenia gravis.
- Dexamethasone 1.5 Mg + Cyclosporine— Increased activity of both cyclosporine and dexamethasone may occur; convulsions have been reported with concurrent use.
Moderate (17)
- Dexamethasone 1.5 Mg + Acidifying Agents— Dexamethasone may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.
- Dexamethasone 1.5 Mg + Aminoglutethimide— Aminoglutethimide may diminish adrenal suppression by dexamethasone.
- Dexamethasone 1.5 Mg + Barbiturates— Barbiturates induce CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.
- Dexamethasone 1.5 Mg + Carbamazepine— Carbamazepine induces CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.
- Dexamethasone 1.5 Mg + Cholestyramine Light— Cholestyramine may increase the clearance of dexamethasone.
- Dexamethasone 1.5 Mg + Digitalis Glycosides— Patients on digitalis glycosides may be at increased risk of arrhythmias due to dexamethasone-induced hypokalemia.
- Dexamethasone 1.5 Mg + Ephedrine— Ephedrine may enhance metabolic clearance of dexamethasone, resulting in decreased blood levels and reduced efficacy.
- Dexamethasone 1.5 Mg + Erythromycin— Erythromycin inhibits CYP 3A4, potentially resulting in increased plasma concentrations of dexamethasone.
- Dexamethasone 1.5 Mg + Estrogens— Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.
- Dexamethasone 1.5 Mg + Indomethacin— False-negative results in dexamethasone suppression test have been reported in patients treated with indomethacin.
- Dexamethasone 1.5 Mg + Isoniazid— Serum concentrations of isoniazid may be decreased when used with dexamethasone.
- Dexamethasone 1.5 Mg + Ketoconazole— Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to resul…
- Dexamethasone 1.5 Mg + Macrolide Antibiotics— Macrolide antibiotics cause significant decrease in dexamethasone clearance, increasing corticosteroid levels.
- Dexamethasone 1.5 Mg + Oral Contraceptives— Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.
- Dexamethasone 1.5 Mg + Phenytoin— Phenytoin induces CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.
- Dexamethasone 1.5 Mg + Rifampin— Rifampin induces CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.
- Dexamethasone 1.5 Mg + Warfarin— Dexamethasone usually inhibits response to warfarin; coagulation indices should be monitored frequently.